Here are answers to readers’ queries on the performance of their stock holdings
I purchased Cairn at ₹300. Kindly give your short-term view.
Thariath
Cairn India (₹270): Since encountering a key resistance at ₹385 in early June 2014, the stock has been on a medium-term downtrend. The short-term trend is also down. While trending down, the stock breached its key support at ₹270 and bounced back last week. Currently, it tests this base level. You can consider averaging and buying the stock with a stop-loss at ₹250 levels.
The indicators are showing signs of upward reversal. The short-term targets on such reversal are ₹290 and ₹300 levels. A strong rally above ₹300 can push the stock higher to ₹311 and ₹330 in the medium term. Next supports are at ₹230 and ₹210.
I want to invest in IDFC for long-term. Could you kindly advise the entry level?
Brij Mohan Lal
IDFC (₹157.4): As long as the stock trades above ₹120, its ongoing intermediate-term uptrend will stay intact.
You can consider buying the stock at current levels and accumulating at key support levels of ₹145, ₹135 and ₹125 levels respectively, while maintaining a stop-loss at ₹120. An upward reversal from these supports can take the stock higher. The subsequent resistance levels are at ₹165 and ₹185 over the medium term.
Kindly give me the future prospects of Kansai Nerolac.
Devidas L Pai
Kansai Nerolac Paints (₹2011.5): After every strong rally, the stock has undergone a sideways consolidation phase which continues for more than a year. The recent sideways consolidation phase came to an end in May 2014 when the stock conclusively broke through the key long-term resistance at ₹1,250 levels. The stock is now in a strong uptrend which is approaching a halt.
Last week, the stock surged 5.7 per cent. It now faces significant resistance at ₹2,100. If its uptrend comes to a halt, it can move sideways in a wide range between ₹1,650 and ₹2,100 levels. Key support below ₹1,650 is at ₹1,530, which is an important trend-deciding level. Plunge below ₹1,530 will mar the intermediate-term uptrend and pull the stock down to ₹1,400 or ₹1,250 levels in the medium term.
What is the medium- and long-term outlook for Marksans Pharma and Aries Agro?
Rajendran N
Marksans Pharma (₹63): Marksans Pharma is a subsidiary of Glenmark Pharmaceuticals. The stock broke out of a significant long-term resistance at ₹10 in December 2013 and has been on a long-term uptrend. It has surged seven-fold this year. Medium-term trend is up.
The stock encountered resistance at around ₹70 in September and has been on a short-term sideways movement in the band between ₹50 and ₹70. A breakout on either direction of this range will decide the next medium-term trend.
A fall below ₹50 can drag the stock down to ₹40 and then to ₹32 levels. Next significant supports are pegged at ₹25 and ₹20. Medium-term bullish outlook will stay intact as long as the stock trades above ₹40. Investors can hold the stock with a stop-loss at ₹40 and exit on a fall below this level. A strong rally above ₹70 can take it higher to ₹80.
Aries Agro (₹107.8): The stock has been on an uptrend across all time frames. Last week, it jumped 18 per cent accompanied by extraordinary volumes, breaking the significant long-term resistance at ₹100.
This rally has strengthened the ongoing uptrend. Traders with a short-term perspective can hold the stock with a stop-loss at ₹90.
Investors with a medium- and long-term horizon can hold with a stop-loss at ₹75. A fall below this level can mar the bullish outlook and pull the stock down to ₹65 or ₹55 levels in the long term.
On the upside, if the stock continues the uptrend, it can encounter key resistance at ₹120 and then at ₹140 in the medium- to long-term.
Send your queries to techtrail@thehindu.co.in
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.